Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Optometry
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2024 / Dec / A-AION or NA-AION?
Research & Innovations

A-AION or NA-AION?

Could newly published research offer a new OCT-based technique for differentiating between the two forms of optic neuropathy?

By The Ophthalmologist 12/27/2024 1 min read

Share

Published in the American Journal of Ophthalmology, a recent study explored the potential of using optical coherence tomography (OCT) biomarkers to differentiate between arteritic anterior ischemic optic neuropathy (A-AION) and non-arteritic anterior ischemic optic neuropathy (NA-AION). A-AION, often associated with giant cell arteritis (GCA), typically presents a poorer visual prognosis compared with NA-AION and demands a different treatment approach, so early differential diagnosis is important.

The study, conducted by researchers from the Department of Ophthalmology at Rigshospitalet, Copenhagen, Denmark, analyzed single-center OCT data from 32 patients, including 8 with A-AION and 24 with NA-AION. It focused on two biomarkers: paracentral acute middle maculopathy (PAMM) and peripapillary intraretinal and subretinal fluid (IRF/SRF). PAMM, a condition marked by ischemic changes in the middle layers of the retina, was found in 50 percent of A-AION cases, but was absent in all NA-AION cases, suggesting it could serve as a useful marker for A-AION. Conversely, extensive peripapillary fluid, particularly involving the macula, was observed in 83 percent of NA-AION patients but was absent in all A-AION cases, indicating it could be used as a potential marker for NA-AION.

Combining these two OCT biomarkers, the researchers found that they could accurately classify 75 percent of patients with AION, based solely on the OCT scans. Indeed, the authors suggest the approach could offer a non-invasive, early diagnostic tool, helping clinicians to initiate appropriate treatments for both A-AION and NA-AION more rapidly.

About the Author(s)

The Ophthalmologist

More Articles by The Ophthalmologist

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: